MCID: THY022
MIFTS: 51

Thymic Carcinoma

Categories: Cancer diseases, Endocrine diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thymic Carcinoma

MalaCards integrated aliases for Thymic Carcinoma:

Name: Thymic Carcinoma 12 77 60 56 15 17
Malignant Thymoma 12 60
Thymoma, Malignant 12

Characteristics:

Orphanet epidemiological data:

60
thymic carcinoma
Inheritance: Not applicable; Age of onset: Adult; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:3284
MeSH 45 D013945
NCIt 51 C7612
SNOMED-CT 69 15949004
ICD10 via Orphanet 35 C37
UMLS via Orphanet 75 C0205969 C1322286
Orphanet 60 ORPHA99868
UMLS 74 C0205969

Summaries for Thymic Carcinoma

Disease Ontology : 12 A thymus cancer that derives from epithelial cells. The tumor cells in a thymic carcinoma look very different from the normal cells of the thymus, grow more quickly, and have usually spread to other parts of the body when the cancer is found.

MalaCards based summary : Thymic Carcinoma, also known as malignant thymoma, is related to lymphoepithelioma-like thymic carcinoma and thymus adenocarcinoma. An important gene associated with Thymic Carcinoma is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways is Central carbon metabolism in cancer. The drugs Fentanyl and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include thymus, thyroid and brain, and related phenotypes are mediastinal lymphadenopathy and neoplasm of the thymus

Wikipedia : 77 Thymic carcinoma is a rare type of thymus gland cancer. It usually spreads, has a high risk of... more...

Related Diseases for Thymic Carcinoma

Diseases related to Thymic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 376)
# Related Disease Score Top Affiliating Genes
1 lymphoepithelioma-like thymic carcinoma 33.2 CD274 CD5 KIT KRT18
2 thymus adenocarcinoma 32.9 CD5 KRT7
3 thymoma 30.5 CD5 EGFR KIT NKX2-1 TP53
4 thymic epithelial tumor 30.1 CD5 KIT
5 thymus cancer 30.1 CD274 CD5 KIT KRT7 MUC1 NKX2-1
6 spindle cell thymoma 30.1 CD5 MUC1
7 ectopic thymus 29.9 CD5 SYP
8 lynch syndrome 29.8 CD274 EGFR TP53
9 adenocarcinoma 29.8 EGFR KIT MUC1 TP53
10 papillary carcinoma 29.7 KRT7 MUC1 NKX2-1
11 mucinous adenocarcinoma 29.6 EGFR KRT7 MUC1 NKX2-1
12 adenoid cystic carcinoma 29.5 KIT KRT7 MUC1 TP53
13 thyroid cancer 29.4 EGFR KIT NKX2-1 TP53
14 gastrointestinal stromal tumor 29.3 EGFR KIT SYP TP53
15 small cell cancer of the lung 28.2 EGFR KIT KRT18 KRT7 NKX2-1 SYP
16 lung cancer 28.0 CD274 EGFR KIT KRT18 KRT7 NKX2-1
17 epithelial malignant thymoma 11.4
18 thymus adenosquamous carcinoma 11.2
19 malignant type ab thymoma 11.1
20 malignant type a thymoma 11.1
21 invasive malignant thymoma 11.1
22 thymus squamous cell carcinoma 11.1
23 noninvasive malignant thymoma 11.1
24 aggressive digital papillary adenocarcinoma 10.5 KIT MUC1
25 hepatoid adenocarcinoma 10.5 EGFR MUC1
26 malignant leydig cell tumor 10.5 KIT KRT7
27 adenoid basal cell carcinoma 10.4 KIT KRT7
28 paget disease, extramammary 10.4 KRT7 MUC1
29 nodular hidradenoma 10.4 KRT7 MUC1
30 adenomyoma 10.4 KRT7 MUC1
31 sertoli-leydig cell tumor 10.4 KRT7 MUC1
32 ampulla of vater adenocarcinoma 10.4 KRT7 MUC1
33 cribriform carcinoma 10.4 KIT KRT7
34 mucinous cystadenocarcinoma 10.4 KRT7 MUC1
35 hidradenoma 10.4 KRT7 MUC1
36 bile duct cystadenocarcinoma 10.4 KRT7 MUC1
37 spindle cell sarcoma 10.4 KRT7 MUC1
38 intratubular embryonal carcinoma 10.4 KIT KRT7
39 bile duct adenoma 10.4 KRT7 MUC1
40 lipoadenoma 10.4 KRT7 MUC1
41 cystadenofibroma 10.4 KRT7 MUC1
42 monophasic synovial sarcoma 10.4 KRT7 MUC1
43 well-differentiated liposarcoma 10.4 KRT7 MUC1
44 vulvar melanoma 10.4 CD274 KIT
45 perineurioma 10.4 KIT MUC1
46 bladder lymphoma 10.4 CD5 KRT7
47 anal canal adenocarcinoma 10.4 CD274 KRT7
48 reticular perineurioma 10.4 KIT MUC1
49 rete testis adenocarcinoma 10.4 KIT NKX2-1
50 thymoma, familial 10.4

Graphical network of the top 20 diseases related to Thymic Carcinoma:



Diseases related to Thymic Carcinoma

Symptoms & Phenotypes for Thymic Carcinoma

Human phenotypes related to Thymic Carcinoma:

60 33 (show all 14)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 mediastinal lymphadenopathy 60 33 hallmark (90%) Very frequent (99-80%) HP:0100721
2 neoplasm of the thymus 60 33 hallmark (90%) Very frequent (99-80%) HP:0100521
3 dyspnea 60 33 frequent (33%) Frequent (79-30%) HP:0002094
4 palpebral edema 60 33 frequent (33%) Frequent (79-30%) HP:0100540
5 chest pain 60 33 frequent (33%) Frequent (79-30%) HP:0100749
6 cough 60 33 frequent (33%) Frequent (79-30%) HP:0012735
7 diaphragmatic paralysis 60 33 frequent (33%) Frequent (79-30%) HP:0006597
8 abnormal vena cava morphology 33 frequent (33%) HP:0005345
9 hyperhidrosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000975
10 fatigue 60 33 occasional (7.5%) Occasional (29-5%) HP:0012378
11 weight loss 60 33 occasional (7.5%) Occasional (29-5%) HP:0001824
12 fatigable weakness 60 33 occasional (7.5%) Occasional (29-5%) HP:0003473
13 edema 60 Frequent (79-30%)
14 abnormality of the vena cava 60 Frequent (79-30%)

MGI Mouse Phenotypes related to Thymic Carcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 9.1 CD274 CD5 EGFR KIT NKX2-1 TP53

Drugs & Therapeutics for Thymic Carcinoma

Drugs for Thymic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
4 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
5 Liver Extracts Phase 3,Phase 1
6 Cola Phase 3,Phase 1,Not Applicable
7 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
8 Anesthetics, Intravenous Phase 3
9 Central Nervous System Depressants Phase 3,Not Applicable
10 Narcotics Phase 3
11 Anesthetics, General Phase 3
12 Adjuvants, Anesthesia Phase 3
13 Analgesics, Opioid Phase 3
14 Analgesics Phase 3,Phase 1
15 Anesthetics Phase 3
16 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
17 Etoposide phosphate Phase 3,Phase 2,Phase 1
18 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
19
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
20
leucovorin Approved Phase 2 58-05-9 6006 143
21
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
22
Belinostat Approved, Investigational Phase 2,Phase 1 866323-14-0
23
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
24
Carboplatin Approved Phase 2 41575-94-4 38904 10339178 498142
25
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
26
Octreotide Approved, Investigational Phase 2 83150-76-9 6400441 383414
27
Bevacizumab Approved, Investigational Phase 2 216974-75-3
28
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
29
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
30
Melphalan Approved Phase 2 148-82-3 460612 4053
31
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 6055-19-2, 50-18-0 2907
32
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
33
Busulfan Approved, Investigational Phase 2 55-98-1 2478
34
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
35
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
36
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
37
Rabeprazole Approved, Investigational Phase 1, Phase 2 117976-89-3 5029
38
Nedaplatin Approved, Investigational Phase 2 95734-82-0
39
nivolumab Approved Phase 2,Phase 1 946414-94-4
40
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
41
Ramucirumab Approved, Investigational Phase 2 947687-13-0
42
Coal tar Approved Phase 1, Phase 2 8007-45-2
43
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
44
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
45
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
46
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
48
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
49
Lexatumumab Investigational Phase 2 845816-02-6
50
Doxil Approved June 1999 Phase 2,Phase 1 31703

Interventional clinical trials:

(show top 50) (show all 55)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
3 A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Completed NCT02623127 Phase 2 Sunitinib
4 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
5 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
6 Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage Completed NCT00589290 Phase 2 Belinostat (PDX101)
7 Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
8 Preoperative Treatment of Patients With High Risk Thymoma Completed NCT00387868 Phase 2 cisplatin and etoposide
9 Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
10 A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
11 Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
12 Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases Completed NCT00003662 Phase 2 busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
13 Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Completed NCT00024076 Phase 2
14 Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors Completed NCT01283945 Phase 1, Phase 2 Lucitanib
15 Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions Completed NCT00003336 Phase 2 busulfan;cyclophosphamide;melphalan;methylprednisolone
16 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
17 Study of Thymosin a1 During Chemoradiotherapy For Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03663764 Phase 2 Thymosin a1
18 Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) Recruiting NCT03134118 Phase 2 Nivolumab
19 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
20 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Recruiting NCT03449173 Phase 2 Sunitinib
21 Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer Recruiting NCT03463460 Phase 2 Sunitinib Malate
22 Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma Recruiting NCT03466827 Phase 2 Selinexor
23 Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery Recruiting NCT03694002 Phase 2 Carboplatin;Paclitaxel
24 Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Recruiting NCT03583086 Phase 1, Phase 2 VEGFR/PDGFR Dual Kinase Inhibitor X-82
25 A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Recruiting NCT01325441 Phase 1, Phase 2 BBI608;Paclitaxel
26 Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy Recruiting NCT03193437 Phase 2 Open Label Selinexor
27 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Recruiting NCT02810418 Phase 1, Phase 2 LMB-100;Nab-Paclitaxel
28 Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Active, not recruiting NCT02049047 Phase 2 Everolimus
29 Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Active, not recruiting NCT01025089 Phase 2 Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
30 Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma Active, not recruiting NCT02364076 Phase 2 Pembrolizumab;Epacadostat
31 Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors Active, not recruiting NCT02636556 Phase 2
32 Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Active, not recruiting NCT01621568 Phase 2 Sunitinib
33 A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Active, not recruiting NCT01364727 Phase 2 Amrubicin
34 Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Terminated NCT01011439 Phase 2 Milciclib Maleate
35 Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy Terminated NCT01301391 Phase 2 Milciclib Maleate
36 Paclitaxel and Cisplatin for Thymic Neoplasm Terminated NCT00818090 Phase 2 paclitaxel and cisplatin
37 Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer Terminated NCT00718809 Phase 2 saracatinib
38 A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Terminated NCT01100944 Phase 1, Phase 2 PXD101with cisplatin+doxorubicin+cyclophosphamide
39 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
40 Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma Completed NCT00314873 Phase 1 Gleevec (imatinib)
41 Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas Completed NCT01143545 Phase 1 Celecoxib;cyclophosphamide
42 Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies Completed NCT00921739 Phase 1
43 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
44 Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03295227 Phase 1 Pembrolizumab
45 Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors Recruiting NCT03102320 Phase 1 Cisplatin;Gemcitabine;Anetumab ravtansine (BAY94-9343)
46 SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access Unknown status NCT02214134
47 Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer Unknown status NCT00372840 Not Applicable
48 Biology of Thymic Tumors Completed NCT00965627
49 Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment Completed NCT03078699 Not Applicable
50 Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy Completed NCT02062632 Not Applicable Doxepin Hydrochloride

Search NIH Clinical Center for Thymic Carcinoma

Genetic Tests for Thymic Carcinoma

Anatomical Context for Thymic Carcinoma

MalaCards organs/tissues related to Thymic Carcinoma:

42
Thymus, Thyroid, Brain, Testes, Prostate, Bone, Lymph Node

Publications for Thymic Carcinoma

Articles related to Thymic Carcinoma:

(show top 50) (show all 673)
# Title Authors Year
1
Nephrotic syndrome: first presentation of lymphoepithelioma-like thymic carcinoma. ( 30592665 )
2019
2
Ectopic cervical well differentiated thymic carcinoma: report of a diagnostically challenging rare case. ( 30477879 )
2019
3
The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma. ( 30600651 )
2019
4
Surgical management of spinal metastases of thymic carcinoma: A case report and literature review. ( 30653174 )
2019
5
A case of brain metastasis of a thymic carcinoma with a review of the literature. ( 30711259 )
2019
6
Laparoscopic dissection for pelvic lymph node recurrence of thymic carcinoma: A case report. ( 30714349 )
2019
7
Concurrent thymic carcinoma and middle lobe syndrome. ( 29600097 )
2018
8
Thymoma and thymic carcinoma associated with multilocular thymic cyst: a clinicopathologic analysis of 18 cases. ( 29945642 )
2018
9
Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. ( 29702286 )
2018
10
Spontaneous remission in large-vessel vasculitis: Takayasu arteritis and paraneoplastic disorder associated with thymic carcinoma. ( 29974801 )
2018
11
Thymic Carcinoma Associated with Cerebellar Degeneration. ( 30756016 )
2018
12
Incidental Detection of Basaloid Thymic Carcinoma With 68Ga-PSMA-11 PET/CT in a Patient With Recurrent Prostate Cancer. ( 29550202 )
2018
13
Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study. ( 29567820 )
2018
14
Thymic carcinoma - a rare case report. ( 29785165 )
2018
15
Apatinib treatment in extensive metastatic advanced thymic carcinoma. ( 29921401 )
2018
16
Robot-assisted en bloc anterior mediastinal mass excision with pericardium and adjacent lung for locally advanced thymic carcinoma. ( 29963404 )
2018
17
Surgery Resection of a Massive Thymic Carcinoma during Urgent Coronary Artery Bypass Grafting. ( 29983810 )
2018
18
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. ( 30033090 )
2018
19
Mutation Ensemble for Response to Programmed Cell Death 1 Inhibition in Thymic Carcinoma. ( 30049379 )
2018
20
Fever of unknown origin caused by intrathyroidal thymic carcinoma. ( 30099866 )
2018
21
A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma. ( 30121390 )
2018
22
Outcomes of patients undergoing surgery for thymic carcinoma: a single-center experience. ( 30174874 )
2018
23
Utility of monoclonal PAX8 antibody for distinguishing intrathyroid thymic carcinoma from follicular cell-derived thyroid carcinoma. ( 30210064 )
2018
24
Metastatic Thymic Carcinoma with Long Survival After Treatment with Sunitinib. ( 30237943 )
2018
25
Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma. ( 30411854 )
2018
26
Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma. ( 30429036 )
2018
27
Survival outcomes after minimally invasive thymectomy for early-stage thymic carcinoma. ( 30430264 )
2018
28
L-Type Amino Acid Transporter 1 Immunoreactivity as a Possible Diagnostic and Prognostic Marker of Thymic Carcinoma. ( 30449824 )
2018
29
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression. ( 30483099 )
2018
30
Systemic treatments for thymoma and thymic carcinoma: A systematic review. ( 30527189 )
2018
31
Morphological assessment of thymic carcinoma through imaging: is computed tomography useful in selecting patients for surgery and in predicting incomplete resection? ( 30631520 )
2018
32
The usefulness of radiographic imaging for predicting the resectability of thymic carcinoma. ( 30631529 )
2018
33
Mutation analysis of the EGFR gene and its downstream signaling pathway in thymic carcinoma patients from a Chinese Han population. ( 27731926 )
2018
34
Leser-Trélat Sign Secondary to Thymic Carcinoma. ( 29103671 )
2018
35
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. ( 29240542 )
2018
36
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. ( 29395863 )
2018
37
Undifferentiated thymic carcinoma with intracranial metastasis in a two-year-old. ( 29411634 )
2018
38
A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma. ( 29467945 )
2018
39
Response to Nivolumab as Salvage Therapy in a Patient with Thymic Carcinoma. ( 29472056 )
2018
40
A Whole-Tumor Histogram Analysis of Apparent Diffusion Coefficient Maps for Differentiating Thymic Carcinoma from Lymphoma. ( 29520195 )
2018
41
A Nomogram Predicting Recurrence and Guiding Adjuvant Radiation for Thymic Carcinoma After Resection. ( 29530769 )
2018
42
Radiographic Predictors of Resectability in Thymic Carcinoma. ( 29534953 )
2018
43
Exclusive meningeal relapse of a malignant thymoma after a complete response with neoadjuvant chemotherapy. ( 29468565 )
2018
44
Changing pattern of secondary cancers among patients with malignant thymoma in the USA. ( 30081670 )
2018
45
Successful treatment of malignant thymoma with sacrum metastases: A case report and review of literature. ( 30572538 )
2018
46
Diffuse Alveolar Hemorrhage Induced by Irinotecan for a Patient with Metastatic Thymic Carcinoma: A Case Report and Literature Review. ( 28674360 )
2017
47
Multicentric reticulohistiocytosis associated with thymic carcinoma. ( 28633354 )
2017
48
Correction: Long term oncological outcome of thymoma and thymic carcinoma - an analysis of 235 cases from a single institution. ( 28931090 )
2017
49
Rare Case of Spinal Cord Compression as Initial Presentation of Thymic Carcinoma. ( 29147447 )
2017
50
High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma. ( 28550415 )
2017

Variations for Thymic Carcinoma

Cosmic variations for Thymic Carcinoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM44380 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 0
2 COSM14140 SMAD4 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1081C>T p.R361C 18:51065548-51065548 0
3 COSM6191487 PREX2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.107G>T p.R36L 8:67952501-67952501 0
4 COSM6191489 NOTCH2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.3359G>A p.C1120Y 1:119937445-119937445 0
5 COSM2006821 KMT2D thymus,NS,thymic carcinoma,undifferentiated carcinoma c.11824C>T p.R3942W 12:49032071-49032071 0
6 COSM133763 KIT thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1657T>A p.Y553N 4:54727425-54727425 0
7 COSM6191682 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2921C>T p.A974V 23:45078488-45078488 0
8 COSM6196604 IL7R thymus,NS,thymic carcinoma,undifferentiated carcinoma c.537+1G>T p.? 5:35871214-35871214 0
9 COSM6191486 FAT1 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12706A>G p.K4236E 4:186596834-186596834 0

Expression for Thymic Carcinoma

Search GEO for disease gene expression data for Thymic Carcinoma.

Pathways for Thymic Carcinoma

Pathways related to Thymic Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.74 EGFR KIT SLC7A5 TP53

GO Terms for Thymic Carcinoma

Biological processes related to Thymic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.26 MUC1 TP53
2 tongue development GO:0043586 9.16 EGFR KIT
3 cerebral cortex cell migration GO:0021795 8.96 EGFR NKX2-1
4 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 8.62 EGFR TP53

Sources for Thymic Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....